Behind every successful Clinical Trial, there is a lot you don’t see

Clinical trials in Europe are often described as harmonized. On paper, that sounds reassuring. In reality, anyone who has managed a study across different countries knows that European clinical research comes with its own complexity, nuance and, sometimes, beautifully coordinated chaos.

Regulatory expectations differ. Ethics Committee processes vary. Site realities are not the same from one country to another. Recruitment assumptions can shift quickly once they meet real-life patient pathways.

To better understand what really happens behind the scenes of a clinical trial, we sat down with Anke, Clinical Operations Director at Novellas Healthcare, who brings more than 25 years of clinical project management experience across multiple study phases. Her expertise lies in transforming complex clinical plans into well-executed trials through clear communication, proactive risk management and strong team alignment.

Not always.

There is a European framework, of course, and harmonization has improved many aspects of clinical research. But sponsors should never assume that Europe works as one single country.

Each country can have different regulatory expectations, Ethics Committee requirements, site processes, contract timelines, budget structures and local operational realities.

That is often where sponsors underestimate the complexity. A study that looks straightforward at central level can become much more complicated once it reaches country and site level.

A lot more than people sometimes imagine.

Before the first patient can be enrolled, the study needs to be carefully prepared. This includes protocol and endpoint design, regulatory and Ethics Committee approvals, site selection, contract and budget negotiations, eCRF setup, IMP logistics, monitoring plans and site training.

A clinical trial does not simply “start”. It is planned, de-risked, aligned and prepared.

That preparation is what allows the study to run safely, compliantly and efficiently once recruitment begins.

Feasibility is the foundation of every successful clinical trial.

But feasibility should never be treated as a checkbox exercise. It is not only about selecting the right sites. It is about understanding whether the protocol is realistic, whether the right patients can actually be reached, whether the timelines are achievable, and whether the operational setup makes sense in the real world.

Good feasibility also means involving local experts, sites and Key Opinion Leaders early enough. Their input can help ensure that endpoints are meaningful, visits are manageable and procedures are practical.

A strong feasibility assessment can save months later in the study.

A CRO does much more than “run the study”.

A strong CRO acts as an extension of the sponsor.

It provides regulatory, operational, clinical, data, quality and compliance support throughout the study lifecycle.

That can include input on study design, feasibility, site strategy, submissions, vendor coordination, monitoring, data review, inspection readiness and risk management.

The role of a CRO is to help sponsors navigate complexity. Ideally, we make complex trials look simple, timelines look achievable and sponsors feel supported throughout the process.

Sponsors expect much more than operational execution.

They want a partner who is proactive, flexible and strategically aligned with their goals. They expect transparency, clear communication, strong quality oversight, inspection readiness and the ability to adapt quickly when timelines, protocols or regulatory requirements change.

Clinical research has become more complex. Sponsors need CROs that can think with them, challenge assumptions when needed and offer tailored solutions instead of applying a one-size-fits-all model.

Today, a CRO needs to be both operationally strong and strategically smart.

Clinical research in Europe is changing quickly.

We see more digital and hybrid trial models, remote monitoring, wearables and patient-friendly designs. There is also a stronger focus on patient-centricity, making participation easier and improving retention.

At the same time, studies are becoming more specialized. Advanced therapies, such as gene therapies, CAR-T treatments and complex biologics, require deep operational and regulatory expertise.

This means sponsors need partners who can keep pace with innovation while maintaining quality, compliance and practical execution.

As early as possible.

Ideally, the conversation should start well before first patient in. Even better, before key protocol, feasibility and site strategy decisions are finalized.

Early collaboration allows the CRO to provide input on protocol feasibility, site selection, operational risks, budget assumptions and regulatory strategy.

The earlier we are involved, the better we can help sponsors avoid delays, align expectations and prepare the study properly from the start.

Do not wait until everything is already decided before involving your CRO.

Clinical trials are much easier to optimize before the plan is locked. Early discussion can help identify risks, improve feasibility, align country and site realities, and create a smoother path toward study start-up.

At Novellas Healthcare, we thrive in that early phase. We bring senior clinical expertise, flexibility and a practical understanding of what it takes to move from strategy to execution.

Because a successful clinical trial is not only about reaching first patient in.

It is about everything you do before that moment to make success possible.

Novellas Healthcare supports sponsors with agile CRO services, senior clinical expertise and hands-on operational support across Europe.